WEX Launches $750M Tender Offer with Odd-Lot Provision Amidst Share Price Decline and Strategic Stake Increase
WEX launched a $750m tender offer to repurchase ~12% of shares at $148-$170/share, prioritizing odd lots.
324 Views
SSI Weekly Highlights: Liquidations, Mergers, and Strategic Developments in Biopharma
Abrdn Diversified Income And Growth is undergoing a wind-down, trading at a 30% discount to NAV, with potential liquidation acceleration.
262 Views
Acelyrin and Alumis Merger Faces Activist Challenges Amid Tang's Higher Offer and Market Skepticism
Acelyrin agreed to an all-stock merger with Alumis, valued at $2.2/share, requiring shareholder approval with 24% support.
553 Views
ADIG Investment Trust: Potential Portfolio Sale Amidst Liquidation Offers 20% Upside
ADIG, a £140m investment trust in liquidation, trades at a 30% discount to its estimated £0.68/share NAV. The trust is in exclusive talks to sell...
270 Views
Strategic Reviews, Mergers, and Asset Sales: Analyzing Upside Potential in Active Portfolio Ideas
Sage Therapeutics rejected Biogen's $7.22/share offer, initiating a strategic review for potential sale, indicating a possible higher premium.
230 Views